Glenmark

Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in Gujarat

... Hospital and the MP Shah Medical College - glenmark Not Only Acts as the Whistle-Blower but Also Disco...udy for its lead COPD/asthma molecule, Oglemilast, glenmark Pharmaceuticals Limited contracted Omnicare Clinic...care suspected fraudulent activity. Without delay, glenmark along with Omnicare carried out the appropriate fo...

FDA Reverses Stance on Removal of Morphine Painkiller

...es," she said. The companies getting warning letters were: Boehringer Ingelheim Roxane Inc., of Columbus, Ohio; Cody Laboratories Inc., Cody, Wyo.; glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Co., Philadelphia; Lehigh Valley Technologies Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Grou...

FDA Warns Drug Makers to Stop Selling Unapproved Prescription Painkillers

...es," she added. The companies getting warning letters are: Boehringer Ingelheim Roxane Inc., of Columbus, Ohio; Cody Laboratories Inc., Cody, Wyo.; glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Co., Philadelphia; Lehigh Valley Technologies Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Grou...

Lilly Reports Fourth-Quarter and Full-Year 2008 Results

...nd development associated with the MacroGenics and glenmark in-licensings. ... charge associated with the MacroGenics and glenmark in-licensings - .05 ...nd development associated with the MacroGenics and glenmark in-licensings. The company recognized asset...

Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals

...ths among children under five years. Crofelemer is also licensed to glenmark Pharmaceuticals, Ltd. of Mumbai, India in 140 emerging and developing count...China for diarrhea indications. In conjunction with this license to Salix, glenmark and Salix have entered into a commercial supply agreement for crofelemer AP...

Lilly Caps Successful Year with Strong Fourth-Quarter Results

...ub-family 1 (TRPV1) antagonist molecules from glenmark Pharmaceuticals S.A. The lead compound, GRC 6...lopment charges associated with MacroGenics and glenmark in- licensings .05...nd Ivy acquisitions and OSI, MacroGenics and glenmark in-licensing transactions ...

Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy

... portfolio of TRPV1 antagonists acquired from glenmark Pharmaceuticals, is currently in early Phase II ...ICOS, Hypnion, and Ivy acquisitions and OSI, glenmark and MacroGenics in-licensing transactions ...ICOS, Hypnion, and Ivy acquisitions and OSI, glenmark and MacroGenics in-licensing transactions ...

Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib

... Indian Pharmaceuticals companies glenmark pharma and Nicholas Piramal has withdrawn their dr...as had about Rupees 12 crores. Mr. A.S. Mohanty of glenmark said, “The Indian market abides by the norms laid ...recalled all the existing stocks from the market”. glenmark has plans of replacing Valdecoxib with other alter...

Glenmark’s new molecule to go through trial

... glenmark Pharmaceuticals Ltd today said its newly- found andti-diabetic/anti-obesity... clinical trials by later this year. Mr Glenn Saldanha, Executive Director, glenmark pharmaceuticals, told newspersons that the company’s R&D team has establish...

Glenmark in Medical Technology

Lilly and Glenmark Pharmaceuticals Announce License Agreement

Lilly to Acquire Next Generation Molecule GRC 6211 for the Potential Treatment of Pain, Including Osteoarthritic Pain INDIANAPOLIS and MUMBAI, India, Oct. 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has entered into an agreement with Gl...

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

...gical diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources. Napo has partnerships with glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. The Company has also established an alliance with Direct Relief International to p...

Napo Presents at ISPOR Meeting in Toronto

...gical diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources. Napo has partnerships with glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. For more information please visit http://www.napopharma.com . About ISPOR I...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

...ult infectious diarrhea) conducted by its partner, glenmark Pharmaceuticals Limited (BSE: Glenmark). The prima...d causality was not attributed to the treatment. glenmark is Napo's exclusive licensee for crofelemer in ove...alization of royalties from sales of crofelemer by glenmark in over 140 countries, and may address the devasta...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

...artners, is pleased to announce that its licensee, glenmark Pharmaceuticals Limited, ("Glenmark" - BSE - id 53...mer trial is expected to conclude in six months. glenmark licensed crofelemer for the indications of acute i...ndications are approved in Glenmark's territories, glenmark will pay ascending royalties to Napo on sales of c...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

..., but future products may be in-licensed from other sources. Napo has partnerships with Trine Pharmaceuticals, Inc. of the United States of America; glenmark Pharmaceuticals Limited of India; and AsiaPharm Group Ltd. of China. For more information please visit

MUMBAI, India, December 11 /PRNewswire/ -- - SCRIP Awards Recognises the Best and Brightest in the Pharmaceutical and Biotech Industries Worldwide - Glenmark is the Only Indian Company to Have Received This Prestigious Recognition The best and brightest of the p...

PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy

BOSTON, Oct. 29 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, in partnership with Glenmark Pharmaceuticals Ltd, today announced that it has been recognized by the Good Clinical Practice Journal (GCPj) as the ...

Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials

...rt by end 2009 - IND approved by USFDA - glenmark takes a step closer towards becoming the first ...the USFDA to carry out a clinical study in the US. glenmark continues to be in discussions with various licens... mellitus". said Mr. Glenn Saldanha, MD & CEO, glenmark Pharmaceuticals Limited. He further added "With th...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

...COS, Hypnion, and Ivy acquisitions (2007) and in-licensing transactions with BioMS and TransPharma (2008) and OSI, MacroGenics and glenmark (2007) .10 .63 Benefit from resolution of IRS audit (.19) - Charge for a reduction in expected insurance r...

Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)

...), Phase 2 -- CRO-PED for paediatric diarrhoea, Phase 1 The FDA has granted fast-track status to CRO-IBS and CRO-HIV. Napo has partnerships with glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. The Company has also established an alliance with Direct Relief International to p...

Lilly Reports Solid Second-Quarter Results

...ith ICOS, Hypnion, and Ivy acquisitions (2007) and in-licensing transactions with BioMS and TransPharma (2008) and OSI, MacroGenics and glenmark (2007) .07 .63 Benefit from resolution of IRS audit (.19) - Pro forma as if the I...

Lilly Reports Solid First-Quarter Results

...h & development charges associated with BioMS Medical in-licensing (2008) and ICOS, Hypnion, and Ivy acquisitions and OSI, MacroGenics and glenmark in-licensings (2007) .05 .63 Pro forma as if the ICOS acquisition was completed on January 1, 2007 ...

Lilly Announces Termination of AIR Insulin Program

...cess research & development charges associated with ICOS, Hypnion, - .63 and Ivy acquisitions and OSI, MacroGenics and glenmark in- licensing transactions Include pro forma as if the ICOS acquisition was completed on January 1, 2006 - ...

Lilly and BioMS Medical Announce Global Licensing and Development Agreement

... - .06 Eliminate in-process research & development charges associated with ICOS, Hypnion, and Ivy acquisitions and OSI, glenmark and MacroGenics in-licensing transactions - .63 Include pro forma as if the ICOS acquisition was completed on January 1, ...